Quick Answer
INTEGRATED BIOPHARMA INC reported Long-Term Debt of $7.0 thousand for fiscal year 2023.
INTEGRATED BIOPHARMA INC Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2023 | $7.0K | -86.8% |
| 2022 | $53.0K | — |
| 2021 | $0.00 | -100.0% |
| 2020 | $1.44M | -47.2% |
| 2019 | $2.72M | -24.9% |
| 2018 | $3.62M | -14.6% |
| 2017 | $4.25M | -19.0% |
| 2016 | $5.24M | +33.0% |
| 2015 | $3.94M | -9.6% |
| 2014 | $4.36M | -10.8% |
| 2013 | $4.89M | +4.0% |
| 2012 | $4.70M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| March 31, 2024 | $0.00 | -100.0% | -100.0% |
| June 30, 2023 | $7.0K | -86.8% | -61.1% |
| March 31, 2023 | $18.0K | — | -35.7% |
| December 31, 2022 | $28.0K | — | -28.2% |
| September 30, 2022 | $39.0K | — | -26.4% |
| June 30, 2022 | $53.0K | — | +32.5% |
| March 31, 2021 | $40.0K | -97.6% | -91.5% |
| December 31, 2020 | $470.0K | -75.3% | -28.1% |
- INTEGRATED BIOPHARMA INC showed a decrease of -86.8% in Long-Term Debt compared to the prior fiscal year.
- Over the 2012–2023 period, INTEGRATED BIOPHARMA INC’s long-term debt has declined by 99.9% (from $4.70 million to $7.0 thousand).
- The most recent figure is from INTEGRATED BIOPHARMA INC’s fiscal year 2023 report (Form 10-K), filed with the SEC on September 15, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: